Browse the corpus

REFERENCES Badesch DB, Abman SH, Simonneau G, et al, “Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines,” Chest , 2007, 131(6):1917-28. [PubMed 17565025 ] Galie N, Badesch D, Oudiz R, et al, “Ambrisentan Therapy for Pulmonary Arterial Hypertension,” J Am Col Cardiol , 2005, 46(3):529-35. [PubMed 16053970 ] Langleben D, “Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension,” Clin Chest Med , 2007, 28(1):117-25. [PubMed 17338931 ] McLaughlin VV, Archer SL, Badesch DB, et al, “ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: Developed in Collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association,” J Am Coll Cardiol , 2009, 53(11):1573-619. [PubMed 19389575 ] National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Vatter H and Seifert V, “Ambrisentan, a Non-peptide Endothelin Receptor Antagonist,” Cardiovasc Drug Rev , 2006, 24(1):63-76. [PubMed 16939634 ] Topic 8653 Version 40.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [1004-61.234.146.186-FF4A722CD6-S244013.14]